Sat, Oct 25, 2014, 8:07 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.


camvest 23 posts  |  Last Activity: Oct 16, 2014 3:42 PM Member since: Dec 28, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • The 1 year trend is up both on the money flow and the volume for this stock, especially considering the reverse split and consequent dilution that occurred. Considering that reliable PR has it that people are recovering from a near state of blindness, we can expect to see considerable increases in share price, in spite of volatility which is endemic to the market. Also consider there are going to be an expanding range of therapeutic applications, for instance Dr. Atala in the NPR program mentioned heart and lung disease and other medical conditions. In fact every type of tissue in the body could benefit from this approach. Nothing goes up in a straight line, there is always programmed trading and speculators trying to knock the price down so they can pick up cheap shares and in fact it will be years before everyone with money to invest even finds out about this stock. Also you have scheduled sales of insider shares, why shouldn't they sell, they're going to keep getting options as the price increase so its just a form of income. It's no big deal when you already have a big salary and money invested.

  • Reply to

    Share Price

    by camvest Oct 12, 2014 11:11 PM
    camvest camvest Oct 16, 2014 3:20 PM Flag

    I think I saw in one of the analyst's reports there is a mention that BLT may have to go to market again for more funds. So prescient investors may acting ahead of the trend. Having said that, this might be a real good time to buy more shares, because there could be some very some very important news generated from these trials.

  • That's a pretty big blunder on NPR saying that embryos are destroyed by this therapy. Also no mention there are many ways of obtaining stem cells other than embryonic stem cells. Would have been a good idea to mention at least something of Atala's credentials as well. "Anthony Atala, M.D. is the W.H. Boyce Professor and Director of the Wake Forest Institute for Regenerative Medicine, and Chair of the Department of Urology at Wake Forest School of Medicine in North Carolina. Regenerative medicine is "a practice that aims to refurbish diseased or damaged tissue using the body's own healthy cells."

  • camvest by camvest Oct 16, 2014 12:26 AM Flag

    Bioworld web site has coverage of stem ACTC story "Encouraging data from early trials of embryonic stem cells"

  • camvest by camvest Oct 12, 2014 11:11 PM Flag

    Why the big drop in share price for BLT this morning.

  • camvest by camvest Oct 9, 2014 1:43 PM Flag

    I was reading an article that said the way Ebola infects cells is similar to the way HIV infects cells. Is it possible ddRNAi could be used as a therapy for Ebola as well as HIV?

    Sentiment: Buy

  • camvest camvest Sep 20, 2014 8:10 PM Flag

    Ok I see the article in the recent newsletter, but I just wonder why Calimmune didn't mention Benitec in the SFGATE article.

  • camvest camvest Sep 20, 2014 7:32 PM Flag

    I see news in the linked article about re-engineering stem cells to eliminate the CCR5 receptor but I don't see anything about Benitec's ddRNAi technology. ACalimmune may be using something other than Benitec's patented technology.

  • camvest camvest Sep 20, 2014 6:52 PM Flag

    What do you expect we'll hear, georjji?

  • Reply to

    Why OCATA?

    by diamondsoulforever Sep 10, 2014 10:34 PM
    camvest camvest Sep 10, 2014 11:50 PM Flag

    There's always some stupid BS happening with this company. First the legacy of financial machinations, then Rabin conveniently not registering the sales of his shares, now an unexplained name change to Ocata, a stupid name if I ever heard one. The preliminary proxy states " We are changing our name in order to create a new corporate brand for the Company and emphasize the Company’s focus on developing therapeutics which may have use as treatment for diseases of the eye". What about the myriad other therapies that they are working on. Are the going to create this company just to work specifically on eye related therapies and divide out all the other possible uses for stem cell therapies into other companies? Something fishy is going on here and it demands explanation.

  • Reply to

    Why OCATA?

    by diamondsoulforever Sep 10, 2014 10:34 PM
    camvest camvest Sep 10, 2014 11:26 PM Flag

    I have come to know and love the name Advanced Cell. What possible rationale could there be for changing the name to Ocata. This is a bizarre turn of events and it's unexplained stuff like this that makes me think something continues to be out of joint at this company. Hope someone has a reasonable explanation for this or else its thumbs down.

  • Reply to

    11.85 CENTS

    by ismelmyownfarts Sep 9, 2014 4:15 PM
    camvest camvest Sep 9, 2014 5:47 PM Flag

    Don't sell this. Think in terms of years and this company will be the Microsoft or Apple of stem cells. Money in the bank.

  • Reply to

    Wake up !!!

    by dendro1717 Sep 3, 2014 5:13 PM
    camvest camvest Sep 3, 2014 5:30 PM Flag

    Yes, and vision is just one of many applications for stem cell therapies. This company is truly unusual and just getting stated!

  • Went all the way to $47.25 before dropping back down to around $10 again. Must be the result of institutional buying. If I was an institutional buyer I would be jumping in now because Applied Cell Technology is the Microsoft of Stem Cells. Their therapies will regenerate every part of the body over time, the growth story here is huge, I believe they will even use stem cells to cure cancer. Now I'm going to buy more shares.

  • Reply to

    Share Price

    by camvest Aug 15, 2014 1:44 AM
    camvest camvest Aug 26, 2014 10:16 PM Flag

    I need some rent money.

  • camvest by camvest Aug 15, 2014 1:44 AM Flag

    Is about where it was 2 years ago in spite of the issuance of additional shares. The RS and up-list should increase the demand for shares and if the RS is made from a position of strength (good news) then the share price should increase. If the RS was done from a position of weakness with bad clinical results or dire financial need then the price would fall.

  • Reply to

    LOL the bashers

    by georgejjl Aug 8, 2014 7:03 PM
    camvest camvest Aug 10, 2014 10:37 PM Flag

    Georgejji, I have couple questions to you. One of the questions presented by a reviewer at a board that approved the tests for TT-034 had pose a question about the buildup of some of the short hairpins in the targeted cells. In other words what if there is an uneven distribution of the short hairpins in the targeted or what if the short hairpins produced by the DNA constructs in the targeted cells exceed the virus rna's. Could this result in some form of toxicity or what is the ultimate breakdown and disposal process that occurs to the DNA construct in the nucleus and/or any surplus shRNA in the targeted cells.

  • Reply to


    by pfatt2 Aug 7, 2014 10:50 AM
    camvest camvest Aug 10, 2014 7:43 PM Flag

    Don't worry so much. There will be a reverse split 130/1 along with announcement of clinical trial data, possible publication of article in med journal, up-list to NASDAQ, possible announcement of joint ventures with bio partners, and announcement of further clinical developments. Everything is going to be ok.

  • camvest camvest Aug 9, 2014 11:06 PM Flag

    Christianity is a mind game imposed by the Romans to cement their empire. The Mideast and Africa became Muslim (another mind game) quickly after the Roman Empire fell apart in those areas because Arabs invaded and took over. The Romans were able to defend the remnants of their hegemony in Europe so Christianity remained pre-dominant there and the Illuminati continued the pattern of using their brainwashed pawns as cannon fodder to impose their financial interests and control the population.

  • Reply to

    A few facts about ACTC.

    by freddyaophelps Jul 30, 2014 10:48 AM
    camvest camvest Aug 6, 2014 8:13 PM Flag

    Seems like its a lot better than going blind.

6.91+0.03(+0.44%)Oct 24 3:58 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Deckers Outdoor Corp.
NYSEFri, Oct 24, 2014 4:01 PM EDT
Palo Alto Networks, Inc.
NYSEFri, Oct 24, 2014 4:04 PM EDT